Suriclone (CAS No.: 53813-83-5)
Manus Aktteva Biopharma LLP is an ISO 9001:2015 Certified Global Supplier based in India for the product Suriclone, 53813-83-5.
We offer the product Suriclone, 53813-83-5 from our manufacturer / supplier / principals for your Research and Development / Evaluation or Commercial requirements, based on the product's availability from our network. We can also offer Suriclone, 53813-83-5 intermediates with the supportive technical package required for evaluation.
We respect our customer's requirements of strict regulatory compliance and specification needs by offering the API - Active Pharmaceutical Ingredients and intermediates transparently while offering easy access to manufacturer / supplier / principals with affordable and high-quality raw materials.
If you are looking for the API -Active Pharmaceutical Ingredients Suriclone, 53813-83-5 manufacturer supplier who is reliable and meets your required quality standard requirements in the first place, you are at the right place!
CAS number:
53813-83-5
Chemical Name:
4-Methyl-1-Piperazinecarboxylic Acid [6-(7-Chloro-1,8-Naphthyridin-2-Yl)-5-Oxo-3,7-Dihydro-2H-[1,4]Dithiino[2,3-C]Pyrrol-7-Yl] Ester, Suriclone (CAS No.: 53813-83-5)
Application:
For R&D Purpose
Email To:
Please enter Email Address
Your Email:
Please enter Email Address
Please enter valid Email Address.
Your Name:
Please enter Your Name
Note:
Processing....
Synonym
4-Methylpiperazine-1-Carboxylic Acid [6-(7-Chloro-1,8-Naphthyridin-2-Yl)-5-Keto-3,7-Dihydro-2H-[1,4]Dithiino[2,3-C]Pyrrol-7-Yl] Ester; Suriclone [Ban:Inn], Suriclone (CAS No.: 53813-83-5)
Manufacturer Specifications
Available on request
Packing
Export worthy packing
Material Safety Data Sheet
Available on request
| Product Name |
CAS No. |
|
| 4-Methyl-1-piperazinecarbonyl chloride hydrochloride |
55112-42-0 |
View | Inquire |
- Products protected by valid patents from a manufacturer are not offered for sale in countries where the sale of such products constitutes a patent infringement and its liability is at buyer's risk.
- Products currently covered by valid US Patents are offered for R&D use from a manufacturer in accordance with 35 USC 271 +A13(1)
- Products falling in to controlled substance category / list of schedule drugs shall be exported directly from the manufacturer principals only against receipt of original import permission issued by concerned authorities of the importing country.
- Manus Aktteva Biopharma LLP assumes no responsibility/liability in case of being imparted with goods which infringe intellectual property in any manner whatsoever which includes patent rights of any individual manufacturer. Manus Aktteva makes no representations or warranties of any kind, express or implied, about the originality or reliability with respect to the intellectual property which includes patents of a manufacturer in its products or services for any purpose.
- Manus Aktteva Biopharma LLP warns the sellers not to sell any goods which infringe intellectual property in any manner whatsoever which includes patent rights of any individual or a manufacturer.
- Manus Aktteva Biopharma LLP warns the buyers not to use/procure any goods from a manufacturer to achieve a product which might be knowingly causing an infringement of intellectual property in any manner whatsoever which includes patent rights of any individual manufacturer.
- This website is updated and maintained by Manus Aktteva Biopharma LLP. As a matter of policy, Manus Aktteva Biopharma LLP does not entertain any anonymous or pseudonymous inquiries.
Are you looking for Suriclone (CAS No.: 53813-83-5) with documentation like USDMF, EDMF, CEP / COS, PMDA - JAPAN, DMF - CANADA, TGA - AUSTRALIA, DMF (OPEN PART), DMF (CLOSED PART), MHRA - UK, DMF - KOREA, AIFA - ITALY, TDP, MEDSAFE - NEW ZEALAND, HEALTH CANADA, JDMF, JAPAN - AFM, DMF - CTD, DCGI, ICH, COPP, TDMF, Written Confirmation? Please
click here to send us sourcing request.
Suriclone, 53813-83-5, Manufacturer, Supplier, India, China
Queries
Easy ways to get the answers you need.
+91 79 26463394
+91 79 26463395
